Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction - A Randomized Phase 2 Trial.

NCT03647969 is registered in ClinicalTrials.gov with Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest as lead sponsor.

NCT NCT03647969
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03647969 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction - A Randomized Phase 2 Trial.
Lead sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase
Phase 2
Overall status
Completed
Start date
November 7, 2018
Completion date
July 19, 2024
Enrollment
262 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the stomach, gastroesophageal cancer